Literature DB >> 8931998

Induction chemotherapy followed by allogeneic bone marrow transplantation or aggressive consolidation chemotherapy in childhood acute myeloblastic leukemia. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).

G Michel1, A Baruchel, M D Tabone, B Nelken, T Leblanc, I Thuret, P Bordigoni, C Bergeron, H Esperou-Bourdeau, Y Perel, J P Vannier, L De Lumley, J P Dommergues, J P Lamagnère, G Couillaud, A Auvrignon, G Schaison, G Leverger.   

Abstract

In the LAME89/91 protocol, children with acute myeloid leukemia (AML) who achieved complete remission (CR) after induction chemotherapy, were treated either with allogeneic bone marrow transplantation (BMT) if they had an HLA-compatible related donor or with chemotherapy including high-dose cytarabine. The objectives of this study were to describe the overall results of this strategy and to compare the two post-remission arms. Two hundred and thirty-one children were enrolled in the protocol. Induction chemotherapy consisted of a combination of cytarabine and mitoxantrone. A CR was achieved in 204 children (88%).

Entities:  

Mesh:

Year:  1996        PMID: 8931998     DOI: 10.1007/s00282-996-0169-7

Source DB:  PubMed          Journal:  Hematol Cell Ther        ISSN: 1269-3286


  2 in total

1.  The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study.

Authors:  Jan-Henning Klusmann; Dirk Reinhardt; Martin Zimmermann; Bernhard Kremens; Josef Vormoor; Michael Dworzak; Ursula Creutzig; Thomas Klingebiel
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

Review 2.  Minimising the long-term adverse effects of childhood leukaemia therapy.

Authors:  Claudia Langebrake; Dirk Reinhardt; Jörg Ritter
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.